Health ETFs Gain Traction Amid China Obesity Drug Price Cuts

Novo Nordisk and Eli Lilly are engaging in a strategic price reduction campaign for their blockbuster obesity drugs, Wegovy and Mounjaro, respectively, primarily in China, presenting a potentially significant shift in the pharmaceutical landscape. These moves, revealed on December 29, 2025, have triggered investor concern and subsequently impacted the share prices of both companies. The strategy reflects a calculated move to rapidly gain market share within the world’s largest nation and most populous country.

China’s Obesity Market Drives Aggressive Pricing

The escalating demand for obesity medications, fueled by China’s rapidly increasing prevalence of overweight and obese individuals – projected to represent over 65% of the nation’s 1.4 billion population by 2030 – has created a highly competitive environment. China’s National Health Commission’s figures highlight a significant projected surge in obesity rates, further solidifying the potential for significant market gains. This competitive landscape has prompted Novo Nordisk to lower Wegovy prices by nearly 48% in certain Chinese provinces, bringing the monthly list price down to as little as 987 yuan ($141). Similarly, Eli Lilly has responded with aggressive pricing adjustments for its Mounjaro drug. These reductions underscore a deliberate effort to accelerate market penetration and build patient loyalty.

Strategic Implications and Investor Response

The move by Novo Nordisk and Eli Lilly mirrors previous pricing strategies employed in India and the United States, indicating a global trend towards competitive pricing in the obesity drug market. The immediate reaction from the investment community has been skeptical, leading to a downturn in the share prices of both companies. Investors recognize the potential long-term demand for obesity medications, particularly Wegovy and Mounjaro. However, the intense price competition and the prospect of generic competition within the next few years are raising questions about the sustainability of these companies’ profitability.

Diversification Through Healthcare ETFs

Given the volatility created by this “price war,” many financial advisors are recommending a shift towards diversified Healthcare Exchange-Traded Funds (ETFs). Such ETFs offer a less risky approach to capitalizing on the obesity drug boom while mitigating the potential downsides of investing in individual companies. Several ETFs are ideally positioned to capture the sector’s growth.

Prominent Healthcare ETFs to Consider

• State Street Health Care Select Sector SPDR ETF (XLV): This ETF, with assets of $39.93 billion, provides broad exposure to the healthcare sector, holding significant positions in Eli Lilly (15.18%), Johnson & Johnson (8.82%), and AbbVie (7.19%). XLV has experienced a 13.3% gain over the past year, with an 8 basis point (bps) annual fee.

• Vanguard Health Care ETF (VHT): Valued at $17.7 billion, VHT offers exposure to 417 healthcare companies, including Eli Lilly (12.39%), AbbVie (4.85%), and Johnson & Johnson (4.42%). VHT has seen a 14.2% increase in the last year and operates at a 9 bps annual fee.

• iShares U.S. Healthcare ETF (IYH): This ETF, with $3.57 billion in assets, provides exposure to 103 U.S. healthcare companies and includes significant holdings in Eli Lilly (14.79%), Johnson & Johnson (8.56%), and AbbVie (6.95%). IYH has increased by 12% over the past year and features a 38 bps annual fee.

• iShares Global Healthcare ETF (IXJ): A $4.50 billion fund, IXJ offers exposure to 114 pharmaceutical, biotechnology, and medical device companies, with Eli Lilly (10.77%), Johnson & Johnson (6.29%), and AbbVie (5.10%) as key holdings, achieving a 14.1% gain over the past year with a 38 bps annual fee.

• VanEck Pharmaceutical ETF (PPH): With $1.28 billion in assets, PPH offers exposure to the 26 largest most liquid pharmaceutical companies, dominated by Eli Lilly (20.766%), Novartis (10.04%), Merck (8.91%), and Novo Nordisk (6.45%), with a surge of 21.6% over the past year and a 36 bps annual fee.

Conclusion

The strategic price reductions implemented by Novo Nordisk and Eli Lilly in China represent a pivotal moment in the rapidly evolving obesity drug market. While the long-term outlook for these medications remains promising, investors are increasingly recognizing the importance of diversification through Healthcare Exchange-Traded Funds (ETFs). Such ETFs offer a balanced approach, mitigating risk and promoting exposure to the sector’s considerable growth potential.